COL18A1 and neoplasm: It is plausible that administration of AAV-3TSR and AAV-Fc3TSR at 1 × 1011 vg/mouse i.m. and Bevacizumab at 1 × 1010 vg/mouse i.m. (lower dose to mimic the same magnitude of transgene expression as Fc3TSR) led to expression levels that were higher than the optimal dose for tumor reduction, thus exceeding the narrow U-shaped optimal therapeutic window of TSP-1 and endostatins [26,79,80,81].